Cargando…
Dyslipidaemia Among Children Living with HIV after 48 Weeks of First-line Antiretroviral Therapy
BACKGROUND: Antiretroviral therapy (ART) associated dyslipidaemia has been reported among children living with HIV (CLHIV) in both developed and developing countries. Not much data is available on changes in blood lipid profile among CLHIV on first-line ART in India. Aims: To study the changes in th...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631659/ http://dx.doi.org/10.1093/ofid/ofx163.433 |
_version_ | 1783269526386769920 |
---|---|
author | Perumal Kannabiran, Bhavani C, Padmapriyadarsini N, Sanjeeva G R, Srinivasan Shet, Anita N, Poorana Ganga Devi Reddy, Devarajulu Elumalai, Suresh Wanke, Christine A Swaminathan, Soumya |
author_facet | Perumal Kannabiran, Bhavani C, Padmapriyadarsini N, Sanjeeva G R, Srinivasan Shet, Anita N, Poorana Ganga Devi Reddy, Devarajulu Elumalai, Suresh Wanke, Christine A Swaminathan, Soumya |
author_sort | Perumal Kannabiran, Bhavani |
collection | PubMed |
description | BACKGROUND: Antiretroviral therapy (ART) associated dyslipidaemia has been reported among children living with HIV (CLHIV) in both developed and developing countries. Not much data is available on changes in blood lipid profile among CLHIV on first-line ART in India. Aims: To study the changes in the Lipid profile among CLHIVs, 12 months after initiating a non-nucleoside reverse transcriptase inhibitor-based (NNRTI) ART METHODS: A prospective multicentric study enrolled HIV infected children, between 2-12 years of age, initiating NNRTI-based ART in south India. Clinical details, anthropometry and fasting blood for estimating serum total cholesterol (TC), triglyceride (TGL), high-density cholesterol (HDL-c), low-density cholesterol (LDL-c), plasma viral load and CD4 cell counts was collected. These measurements were repeated at 6(th) and 12(th) month after ART initiation. Proportion of children with abnormal lipid profile at baseline and 12 months after ART were compared using McNemar test. Generalized linear model was applied to predict factors associated with changes in serum lipid levels 12 months post-ART. RESULTS: Of the 393 HIV-infected children, 66 % received Zidovudine and 14 % Stavudine in their ART regimen. After 12 months of ART, TC, LDL-c and HDL-c increased from baseline by a mean of 31mg/dL, 13.7 mg/dL and 19mg/dl, respectively. TC/HDL-c ratio decreased from a mean of 5.1 to 3.5 (all changes, P <0.000). At baseline and 12 months, respectively, TC was >200 mg/dL for 3% and 13% of patients, LDL-c was >130 mg/dL for 5% and 8%, HDL-c was <35 mg/dL for 70% and 16%, and TG were >150 mg/dL for 38% and 24%. Baseline HIV viral load >400 copies/mL (P, 0.01) was associated with increase in HDL-c and lower TG levels (P, 0.008). Baseline CD4 % <15 and younger age group were significantly associated with increase in TC (P, 0.02) and decrease in TGL (P,0.02) after 12-months of ART. CONCLUSION: Significant changes in serum lipid profile occurs early in children started on first-line ART. Increase in the cardio protective HDL-c was proportionally greater than increases in TC or TGL. Regular monitoring of lipid levels will help in early identification of metabolic complications of ART DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-5631659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56316592017-11-07 Dyslipidaemia Among Children Living with HIV after 48 Weeks of First-line Antiretroviral Therapy Perumal Kannabiran, Bhavani C, Padmapriyadarsini N, Sanjeeva G R, Srinivasan Shet, Anita N, Poorana Ganga Devi Reddy, Devarajulu Elumalai, Suresh Wanke, Christine A Swaminathan, Soumya Open Forum Infect Dis Abstracts BACKGROUND: Antiretroviral therapy (ART) associated dyslipidaemia has been reported among children living with HIV (CLHIV) in both developed and developing countries. Not much data is available on changes in blood lipid profile among CLHIV on first-line ART in India. Aims: To study the changes in the Lipid profile among CLHIVs, 12 months after initiating a non-nucleoside reverse transcriptase inhibitor-based (NNRTI) ART METHODS: A prospective multicentric study enrolled HIV infected children, between 2-12 years of age, initiating NNRTI-based ART in south India. Clinical details, anthropometry and fasting blood for estimating serum total cholesterol (TC), triglyceride (TGL), high-density cholesterol (HDL-c), low-density cholesterol (LDL-c), plasma viral load and CD4 cell counts was collected. These measurements were repeated at 6(th) and 12(th) month after ART initiation. Proportion of children with abnormal lipid profile at baseline and 12 months after ART were compared using McNemar test. Generalized linear model was applied to predict factors associated with changes in serum lipid levels 12 months post-ART. RESULTS: Of the 393 HIV-infected children, 66 % received Zidovudine and 14 % Stavudine in their ART regimen. After 12 months of ART, TC, LDL-c and HDL-c increased from baseline by a mean of 31mg/dL, 13.7 mg/dL and 19mg/dl, respectively. TC/HDL-c ratio decreased from a mean of 5.1 to 3.5 (all changes, P <0.000). At baseline and 12 months, respectively, TC was >200 mg/dL for 3% and 13% of patients, LDL-c was >130 mg/dL for 5% and 8%, HDL-c was <35 mg/dL for 70% and 16%, and TG were >150 mg/dL for 38% and 24%. Baseline HIV viral load >400 copies/mL (P, 0.01) was associated with increase in HDL-c and lower TG levels (P, 0.008). Baseline CD4 % <15 and younger age group were significantly associated with increase in TC (P, 0.02) and decrease in TGL (P,0.02) after 12-months of ART. CONCLUSION: Significant changes in serum lipid profile occurs early in children started on first-line ART. Increase in the cardio protective HDL-c was proportionally greater than increases in TC or TGL. Regular monitoring of lipid levels will help in early identification of metabolic complications of ART DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2017-10-04 /pmc/articles/PMC5631659/ http://dx.doi.org/10.1093/ofid/ofx163.433 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Perumal Kannabiran, Bhavani C, Padmapriyadarsini N, Sanjeeva G R, Srinivasan Shet, Anita N, Poorana Ganga Devi Reddy, Devarajulu Elumalai, Suresh Wanke, Christine A Swaminathan, Soumya Dyslipidaemia Among Children Living with HIV after 48 Weeks of First-line Antiretroviral Therapy |
title | Dyslipidaemia Among Children Living with HIV after 48 Weeks of First-line Antiretroviral Therapy |
title_full | Dyslipidaemia Among Children Living with HIV after 48 Weeks of First-line Antiretroviral Therapy |
title_fullStr | Dyslipidaemia Among Children Living with HIV after 48 Weeks of First-line Antiretroviral Therapy |
title_full_unstemmed | Dyslipidaemia Among Children Living with HIV after 48 Weeks of First-line Antiretroviral Therapy |
title_short | Dyslipidaemia Among Children Living with HIV after 48 Weeks of First-line Antiretroviral Therapy |
title_sort | dyslipidaemia among children living with hiv after 48 weeks of first-line antiretroviral therapy |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631659/ http://dx.doi.org/10.1093/ofid/ofx163.433 |
work_keys_str_mv | AT perumalkannabiranbhavani dyslipidaemiaamongchildrenlivingwithhivafter48weeksoffirstlineantiretroviraltherapy AT cpadmapriyadarsini dyslipidaemiaamongchildrenlivingwithhivafter48weeksoffirstlineantiretroviraltherapy AT nsanjeevag dyslipidaemiaamongchildrenlivingwithhivafter48weeksoffirstlineantiretroviraltherapy AT rsrinivasan dyslipidaemiaamongchildrenlivingwithhivafter48weeksoffirstlineantiretroviraltherapy AT shetanita dyslipidaemiaamongchildrenlivingwithhivafter48weeksoffirstlineantiretroviraltherapy AT npooranagangadevi dyslipidaemiaamongchildrenlivingwithhivafter48weeksoffirstlineantiretroviraltherapy AT reddydevarajulu dyslipidaemiaamongchildrenlivingwithhivafter48weeksoffirstlineantiretroviraltherapy AT elumalaisuresh dyslipidaemiaamongchildrenlivingwithhivafter48weeksoffirstlineantiretroviraltherapy AT wankechristinea dyslipidaemiaamongchildrenlivingwithhivafter48weeksoffirstlineantiretroviraltherapy AT swaminathansoumya dyslipidaemiaamongchildrenlivingwithhivafter48weeksoffirstlineantiretroviraltherapy |